StreetInsider.com News Articles

Oracle and AstraZeneca sign agreement to improve clinical trials with AI

Tue, 20 Oct 2026 05:58:01 -0400

Oracle (NYSE: ORCL) and AstraZeneca announced a non-binding agreement to explore how AI and real-world data can be used to identify eligible patients for clinical trials, accelerate evidence generation, and bring research insights into clinical care workflows, according to a press release issued Oct. 20, 2026.

The collaboration plans to combine AstraZeneca's scientific and therapeutic expertise with Oracle's health data, cloud, AI, analytics, and clinical workflow capabilities. Initial disease areas under consideration include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare diseases.

Patient recruitment, described in the release as one of the largest obstacles in clinical trials, is a

Oracle and AstraZeneca sign agreement to improve clinical trials with AI

Tue, 20 Oct 2026 05:58:01 -0400

Patient recruitment, described in the release as one of the largest obstacles in clinical trials, is a

Oracle and AstraZeneca sign agreement to improve clinical trials with AI

Tue, 20 Oct 2026 05:58:01 -0400

Patient recruitment, described in the release as one of the largest obstacles in clinical trials, is a

Oracle and AstraZeneca sign agreement to improve clinical trials with AI

Tue, 20 Oct 2026 05:58:01 -0400

Patient recruitment, described in the release as one of the largest obstacles in clinical trials, is a

AstraZeneca to present data from four Phase III trials at ESMO 2026

Mon, 19 Oct 2026 07:03:57 -0400

AstraZeneca (NYSE: AZN) announced it will present data from more than 100 abstracts at the European Society for Medical Oncology Congress, scheduled for October 23-27, 2026, including results from five pivotal Phase III trials, four of which will be featured in Presidential Symposia.

Among the highlights, the CLARITY-Gastric01 trial will present overall survival data for sonesitatug vedotin, a Claudin-18.2-targeting antibody drug conjugate, in patients with second-line or later CLDN18.2-positive advanced gastric or gastroesophageal junction cancers. According to the press release, this is the first Phase III trial to show a statistically significant overall survival benefit with an anti-CLDN18.2 antibody drug conjugate

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitini

Mon, 19 Oct 2026 07:00:00 -0400

CLARITY-Gastric01 data will demonstrate potential of Sone-Ve to establish new treatment for broad population of CLDN18.2-positive gastric cancer patients

SAFFRON results will highlight clinical benefit of adding savolitinib to backbone TAGRISSO in MET-driven 2nd-line EGFRm lung cancer

VOLGA and DeLLphi-305 data will showcase the transformative potential of combining IMFINZI with novel agents to set new standards of care in bladder and small cell lung cancer

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca advances its ambition to revolutionize cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October 23-27,

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitini

Mon, 19 Oct 2026 07:00:00 -0400

CLARITY-Gastric01 data will demonstrate potential of Sone-Ve to establish new treatment for broad population of CLDN18.2-positive gastric cancer patients

SAFFRON results will highlight clinical benefit of adding savolitinib to backbone TAGRISSO in MET-driven 2nd-line EGFRm lung cancer

VOLGA and DeLLphi-305 data will showcase the transformative potential of combining IMFINZI with novel agents to set new standards of care in bladder and small cell lung cancer

AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP139 at HSBC

Mon, 19 Oct 2026 01:31:47 -0400

HSBC analyst Rajesh Kumar lowered the price target on AstraZeneca (AZN:LN) (NASDAQ: AZN) to GBP139.00 (from GBP139.20) while maintaining a Hold rating.

AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP139 at HSBC

Mon, 19 Oct 2026 01:31:47 -0400

HSBC analyst Rajesh Kumar lowered the price target on AstraZeneca (AZN:LN) (NASDAQ: AZN) to GBP139.00 (from GBP139.20) while maintaining a Hold rating.

AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP139 at HSBC

Mon, 19 Oct 2026 01:31:47 -0400

HSBC analyst Rajesh Kumar lowered the price target on AstraZeneca (AZN:LN) (NASDAQ: AZN) to GBP139.00 (from GBP139.20) while maintaining a Hold rating.

AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP139 at HSBC

Mon, 19 Oct 2026 01:31:47 -0400

HSBC analyst Rajesh Kumar lowered the price target on AstraZeneca (AZN:LN) (NASDAQ: AZN) to GBP139.00 (from GBP139.20) while maintaining a Hold rating.

AstraZeneca (AZN) spreader of 11694 contracts of October 170, January 180 and January 210 calls as share price up 3.2%

Thu, 15 Oct 2026 14:12:45 -0400

AstraZeneca (NASDAQ: AZN) 30-day option implied volatility is at 33; compared to its 52-week range of 22 to 42 with a focus on a spreader of 11694 contracts of October 170, January 180 and January 210 calls as share price up 3.2%.

AstraZeneca partners with insitro on AI-driven cardiometabolic drug discovery

Thu, 15 Oct 2026 06:12:36 -0400

AstraZeneca (NASDAQ: AZN) has entered into a drug discovery collaboration and licensing agreement with insitro, an artificial intelligence therapeutics company, according to a company statement dated October 15, 2026.

The collaboration will use AI systems to identify drug targets and develop therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.

AstraZeneca partners with insitro on AI-driven cardiometabolic drug discovery

Thu, 15 Oct 2026 06:12:36 -0400

The collaboration will use AI systems to identify drug targets and develop therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.

Myriad Genetics and SOPHiA Genetics team up on prostate cancer test

Thu, 08 Oct 2026 09:01:21 -0400

Myriad Genetics (NASDAQ: MYGN) and SOPHiA Genetics (NASDAQ: SOPH) announced a collaboration to advance a prostate cancer-specific genomic instability score (PrGIS) technology, working alongside AstraZeneca (NYSE: AZN) to support precision oncology approaches.

PrGIS is a biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. Myriad developed the technology using its MyChoice CDx test, currently available as a companion diagnostic in ovarian cancer, which will produce the PrGIS score as the company pursues prostate cancer as a new indication.

The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines

Myriad Genetics and SOPHiA Genetics team up on prostate cancer test

Thu, 08 Oct 2026 09:01:21 -0400

The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines

Myriad Genetics and SOPHiA Genetics team up on prostate cancer test

Thu, 08 Oct 2026 09:01:21 -0400

The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology